Randomized Clinical Trial to Determine the Effectiveness of CO-Oximetry and Anti-Smoking Brief Advice in a Cohort of Kidney Transplant Patients Who Smoke by Seijo Bestilleiro, Rocío et al.





International Journal of Medical Sciences 
2020; 17(17): 2673-2684. doi: 10.7150/ijms.49401 
Research Paper 
Randomized clinical trial to determine the effectiveness 
of CO-oximetry and anti-smoking brief advice in a 
cohort of kidney transplant patients who smoke 
Rocio Seijo-Bestilleiro1, Teresa Seoane-Pillado1, Sonia Pertega-Diaz1, Cristina González-Martín2, Francisco 
Valdes-Cañedo3, Vanesa Balboa-Barreiro1, Constantino Fernandez-Rivera3, Angel Alonso-Hernandez3, 
Mercedes Cao-Vilariño3, Vicente Gil-Guillen4, Mª Teresa Garcia-Rodriguez2 
1. Clinical Epidemiology and Biostatistics Unit, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A 
Coruña (CHUAC), SERGAS, Universidade da Coruña, A Coruña 
2. Grupo de Investigacion Reumatologia y Salud Pública. Investigación en enfermería y cuidados de la salud. Complejo Hospitalario Universitario A Coruña 
(CHUAC), SERGAS, As Xubias 84, 15006 A Coruña. Universidade da Coruña (UDC) (A Coruña, España).  
3. Nephrology Department, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), 
SERGAS, Universidade da Coruña, A Coruña 
4. Department of Clinical Medicine; University Miguel Hernandez of San Juan de Alicante  
 Corresponding author: González-Martín, Cristina. Grupo de Investigacion Reumatologia y Salud Pública. Investigación en enfermería y cuidados de la salud. 
Complejo Hospitalario Universitario A Coruña (CHUAC), SERGAS, As Xubias 84, 15006 A Coruña. Universidade da Coruña (UDC) (A Coruña, España). Mail: 
cristina.gmartin@udc.es. Phone: 34981178217. Fax: 34981178212 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2020.06.12; Accepted: 2020.08.25; Published: 2020.09.23 
Abstract 
Background: measure the efficacy of exhaled carbon monoxide (CO) measurement plus brief advisory 
sessions to reduce smoking exposure and smoking behaviour in kidney transplant recipients. 
Methods: Randomized, controlled, open-label clinical trial at a Spanish hospital.Smoking kidney 
transplant recipients giving their consent to participate were randomized to control (brief advice, n=63) 
or intervention group (brief advisory session plus measuring exhaled CO, n=59).  
Measurements: Sociodemographic characteristics, cardiovascular risk factors, treatment, rejection 
episodes, infections, self-reported smoking, drug use, level of dependence and motivation to stop 
smoking (Fagerström’s and Richmond’s test) and stage of change (Prochaska and DiClemente’s Stages). 
Efficacy was assessed at 3, 6, 9 and 12 months as: cotinine test, CO levels in exhaled air, nicotine 
dependence, motivational stages of change, motivation to stop smoking, pattern of tobacco use and 
smoking cessation rates. 
Logistic regression models were computed. 
Results: At 12 months of follow-up, differences were found in exhaled CO between the intervention and 
control group(6.1±6.8vs.10.2±9.7ppm;p=0.028). Carboxyhemoglobin levels were lower in the 
intervention group as well as the positive cotinine test (1.2±1.2%vs.2.0±2.4%;p=0.039),(53.4%vs.74.2%). 
At 12 months, intervention reduces the probability of a positive urine test by 28%. 
Conclusions: Co-oximetry is a clinically relevant intervention for reduction of tobacco exposure in 
kidney transplant recipients. 
Key words: “Smoking cessation”, “Kidney transplantation”, “Controlled clinical trial”,” Carbon monoxide”, 
”Nicotine dependence”. 
Background 
Smoking is a major public health issue that leads 
to avoidable mortality and morbidity. It is associated 
with cardiovascular disease, cerebrovascular disease, 
arteriosclerosis, cancer and all-cause mortality [1, 2]. 
Nicotine acts on cholinergic receptors through 








neurotransmitters such as epinephrine, dopamine, 
acetylcholine, serotonin, vasopressin, glutamate, 
nitric oxide, calcitonin and beta endorphin. It is for 
this reason that nicotine may contribute to an 
increased risk of cardiovascular episodes caused by 
temporary surges in arterial pressure, coronary 
vasoconstriction and damage to the endothelial wall 
[1, 3]. 
There is extensive documented evidence of the 
action of tobacco on renal function as a predictor of 
chronic kidney disease [4]. Furthermore, we found a 
bibliography that links tobacco with renal function as 
a predictor of chronic kidney disease[5].  
Literature has documented the connection 
between smoking and kidney failure among the 
general public: examples include MRFIT studies[6], 
the study by Pinto-Sietsma et al.[7], PREVEND[8], the 
study by Briganti et al.[9] and the study conducted by 
Verhave et al.[10]. This connection has also been 
detected in diabetic patients as a factor that 
accelerates kidney failure, shortening the time before 
dialysis is required[11]. 
The presence of chronic kidney disease is 
considered to be independent of the cardiovascular 
risk marker. Preventing or delaying the appearance of 
chronic kidney disease is essential, as it is associated 
with a greater cardiovascular risk (CVR) which 
increases in line with the degree of kidney failure and 
albumin excretion rates. This association between the 
degree of decreased glomerular filtration and a higher 
CVR is also present in relation to the risk of death and 
hospitalization[12]. 
Clinical evidence also indicates that smoking has 
serious negative effects on a number of kidney 
diseases, including diabetic nephropathy, 
hypertensive nephropathy and primary glomerular 
diseases, as well as on patients on chronic 
haemodialysis and in kidney transplanted patients, 
who are at a greater risk of cardiovascular disease and 
cancer than the general population[13]. Smoking is 
therefore a considerable risk factor in this patient 
group.  
Studies have revealed that the prevalence of 
smoking varies enormously among kidney transplant 
recipients. Earlier research carried out by our group 
showed that up to 41.7% of kidney transplanted 
patients at our centres were smokers at the time of 
transplant and around 15% continued to smoke 
following their transplant[14]. Although this figure is 
not particularly high, the impact of smoking on the 
probability of cardiovascular episodes in monitoring 
kidney transplant recipients is clinically relevant. As 
stated in an earlier article[14], the number of patients 
need to treat (NNT) that would have to stop smoking 
to prevent a cardiovascular event at 5 and 10 year 
follow up was 7 and 4 respectively.  
A systematic review[15] identified 12 studies 
during the period between 1968 and 2009 reporting on 
the effect of smoking on kidney transplant survival. 
Although the results of some of the studies reviewed 
were contradictory, in general, smoking was linked to 
a higher risk of graft loss and death. In turn, other 
studies have shown that smoking is associated with a 
higher rate of graft loss and lower survival levels of 
kidney transplanted patients[16]. 
The benefits of giving up smoking have been 
proved in a wide group of cardiovascular disease 
patients[17, 18].  
Non-pharmacological methods are inexpensive 
and easy to implement and can also be particularly 
suitable for transplant patients, who are usually 
polymedicated. Non-pharmacological interventions 
to treat tobacco dependence include advice from 
health professionals, self-help, proactive telephone 
advisory services, group or individual counselling, 
material support and social treatment[19]. 
All smokers should receive advice on how to 
stop smoking. Even relatively brief advice has been 
proved to be effective[20]. 
A number of projects are currently underway to 
determine the effectiveness of co-oximetry and brief 
advice on giving up smoking[21, 22]. Measuring CO 
levels in the air exhaled by smokers could encourage 
them to stop smoking or prove a useful tool in 
monitoring progress in the process of giving up.  
Despite the proven impact of smoking on 
cardiovascular risk and the progression of chronic 
kidney disease, we have been unable to find any 
studies that assess the effects of anti-smoking 
interventions in patients with chronic kidney failure 
or in kidney transplant patients[23]. 
The performance of a co-oximetry, a simple test 
in which the patient can see a number and a color that 
indicates the amount of carbon monoxide and exhaled 
carboxyhemoglobin and with which the patient can 
see if it has improved compared to previous visits, has 
proven to be more effective in achieving cessation of 
smoking [24,25].  
The object of this study is to determine the 
efficacy of measuring exhaled carbon monoxide (CO) 
by Co-oximetry, combined with brief advice, on 
giving up smoking at 12 months, in comparison with 
brief advice only, in smoking kidney transplant 
recipients at the pre-contemplation and 
contemplation or preparation stages, in relation to the 
following outcomes: negative cotinine urine test; 
carbon monoxide levels in exhaled air (CO) by 
Co-oximetry; degree of nicotine dependences 
(Fagerström’s test); motivation for change (Prochaska 
and DiClemente’s stages of change); motivation to 




stop smoking (Richmond’s test); self-reported 
smoking and smoking cessation rates.  
The object of this study is to determine the 
efficacy of measuring exhaled carbon monoxide (CO) 
by Co-oximetry, combined with brief advice, on 
giving up smoking, in comparison with brief advice 
only, in smoking kidney transplant recipients. 
Methods 
The design of this study was previously 
published [26] in accordance with CONSORT 
guidelines. Participant flow chart is shown in Fig 1. 
Briefly, smoker patients who met eligibility 
criteria were recruited in the scheduled routine visits 
to the hospital and informed about the study 
objectives. After giving informed consent to 
participate in the study, patients were randomized 
either to the control or the intervention group 
according to the following protocol: 
a) Control group: brief smoking cessation 
advice session [27] 
b) Intervention group: brief smoking 
cessation advice plus exhaled CO measurement by 
CO-oximetry  
Trial design 
Randomized, controlled and open-label clinical 
trial with parallel groups set in the Nephrology 
Department at the Complexo Hospitalario 
Universitario A Coruña (northwest Spain). 
This study was registered after patient 
recruitment began but before completion of data 
analysis, as both our institution and the funding 
agency only required the approval of a Research 
Ethics Committee to conduct the study. Trial registry 
can be found at the ISRCTN registry (Identifier: 
ISRCTN16615772) and with the European Clinical 
Trials Database (EudraCT number 2015-002009-12). 
Participants 
All kidney transplanted patients attending 
specialized consultations at the Nephrology 
department during the study period (January 2012- 
December 2015), who met the inclusion criteria, were 




Fig 1. CONSORT flow chart. 






• Adult (over 18 years of age) kidney transplant 
recipients who smoked, with functioning 
allograft, who underwent primary or repeated 
renal transplantation from a cadaveric or a living 
donor in the A Coruña Hospital between 1981 
and 2014. 
• Current daily smokers. Smoking status was 
defined according to the WHO classification. 
Therefore, a patient was considered a current 
daily smoker if they reported daily smoking 
during the previous month, irrespective of the 
number of cigarettes smoked. 
• Patients in the pre-contemplation, contemplation 
or preparation stages, based on Prochaska and 
DiClemente’s transtheoretical model [28]. 
Exclusion criteria 
• Smokers attempting to stop smoking, patients 
with terminal illness or mental disability that 
prevented them from participating. 
Interventions 
During the baseline visit (visit 1) patients 
included in the study control group were given a brief 
advisory session about giving up smoking. This was 
firm, concise, personalized (trying to find the most 
important motivations for each patient) and 
appropriate to the phase towards cessation they were 
in. It included information about the negative effects 
of tobacco on their health and an insight into the 
principal advantages of giving up smoking[27]. 
Patients included in the intervention group 
received the brief advisory session, as did the patients 
who belong to the control group, who were also 
administered Co-oximetry. This exploration 
determines amount of CO present in the subject’s 
body. The patient took a deep breath and held it for 15 
seconds, followed by a slow, long and complete 
exhalation. After a few seconds the oximeter indicator 
became stable and marked the exact number of 
particles per million (ppm) of CO in the subject’s 
exhaled air. Follow-up visits took place at 3 months 
(visit 2), 6 months (visit 3) and 9 months (visit 4). At 
each of these moments the anti-smoking advice was 
repeated in the control group and anti-smoking 
advice plus Co-oximetry repeated in the intervention 
group (Table 2). At the 12-month (visit 5) visit, the 
anti-smoking advice was given to both groups as well 
as Co-oximetry. 
The device used was Bedfont Micro Smokerlyzer 
Breath Carbon Monoxide Monitor, made in UK. It has 
been calibrated prior to its use. We do not include it in 
methods for not advertising it, we understand that 
there are several in the market. 
Outcomes 
The effectiveness of both interventions was 
assessed at 3, 6, 9 and 12 months after inclusion in the 
study. The following outcomes were investigated: 
Smoking habit cessation, confirmed by a 
negative urinary cotinine test (intervention was 
considered effective if the test results were lower than 
100 ng/ml), Carbon monoxide (CO) levels in exhaled 
air measured by Co-oximetry, Change in nicotine 
dependence (measured according to the Fagerström 
test[29]), Variation in the motivational stage of change 
(according to the Prochaska and DiClemente’s Stages 
of Change model [28]), Change in motivation to 
giving up smoking (according to the Richmond test 
[30]), Self-reported abandonment of smoking and a 
Reduction in the number of cigarettes smoked per day 
as reported by the patient. 
This measure corresponding to the threshold 
<100ng / ml was used given that it was the one used 
in the test strips with which the study was carried out. 
Sample size 
Meta-analyses have shown that around 5–6 % of 
smokers stop after the brief advisory session from a 
physician [27]. This study was designed to include 
n=120 patient (60 per group). This sample size would 
allow to detect as statistically significant differences in 
exhaled CO values of 5 ppm of higher (standard 
deviation +-10 ppm) between groups, as well as a 18% 
increase in the smoking cessation rate, with a 95% 
confidence (alfa=0.05) and 80% power (beta=0.20). 
Randomisation 
Computerized allocation to each of the study 
groups was conducted in advance. The assignment 
sequence was generated by a person who was not 
responsible for determining patient eligibility. By the 
nature of the interventions neither the researchers nor 
the patients could be blinding to the assignment. 
Blinding 
This was an open clinical trial. Only those 
assessing outcomes were blinded after assignment to 
interventions. 
Statistical methods 
Comparability of intervention and control 
groups was checked in terms of the similarity of the 
distribution of the variables of interest at baseline. The 
response that patients rate, at different time points in 
the follow-up, was compared in both arms of the 
study according to the outcomes studied. 
The chi-square test or Fisher’s exact test was 
used to compare proportions. Student’s t test was 




used to compare means between groups with normal 
distribution data. The Mann-Whitney test was used to 
compare quantitative variables between groups in 
case of a non-normal distribution, determined by the 
Kolmogorov-Smirnov test. 
Correlations between quantitative measure-
ments was determined by the Spearman’s rho 
correlation coefficient. Matched-pair data analysis 
was also computed. Therefore, to evaluate the 
differences within each group at different time points, 
McNemar’s test and Wilcoxon’s signed ranks test 
were calculated. 
Additionally, clinical relevance of intervention 
was studied by calculating the relative risk (RR), 
relative risk reduction (RRR), absolute risk reduction 
(ARR) and patient number needed to treat (NNT) at 
different times during follow-up. All these measures 
were presented with their confidence interval at 95 %. 
To analyze the association of using Co-oximetry 
in each of the outcomes, adjusting for potential 
confounders, multivariate linear and logistic 
regression models were employed. 
Variables with statistical significance p <0.10 in 
the bivariate analysis were selected for inclusion in 
the multivariate regression analysis. A modelling 
strategy of successive step-wise regression. 
The degree of agreement between self-reported 
smoking, Co-oximetry results and the test results of 
urinary cotinine levels at 3, 6, 9 and 12 months after 
surgery was considered and assessed by means of the 
kappa index. 
The validity of self-reported smoking by patients 
regarding the results of the Co-oximetry and urinary 
cotinine test was studied. Sensitivity, specificity and 
positive and negative predictive values were 
determined, together with their 95 % confidence 
interval. 
All analyses were conducted by intention-to- 
treat. Analyses were conducted using the statistical 
package Statistical Package for the Social Sciences 
software, version 19.0 (SPSS, Chicago, IL, USA). 
Ethics 
Informed consent of the patients and the 
approval from the regional Ethics Committee for 
Clinical Research (Comité Autonómico de Ética da 
Investigación de Galicia, EC registry code 2011/061) 
was obtained. 
Results 
Baseline data:  
The characteristics of the intervention and 
control groups are shown in Table 1. 
This table reveals no significant differences in 
socio-demographic variables or co-morbidity pre or 
post-transplant, or in the follow up times between 
both groups. Specifically, the groups are comparable 
in the case of the following variables: transplant age; 
transplant time in years; patient age at the start of the 
clinical trial and gender. Likewise, no significant 
differences were observed in pre-transplant 
co-morbidity between both groups in terms of the 
pre-transplant dialysis time; total cholesterol level; 
prevalence of obesity; prevalence of pre-transplant 
diabetes; left ventricular hypertrophy; pre-transplant 
cardiovascular episodes and previous malign 
tumours. No differences were detected 
post-transplant between the two groups in terms of 
cold ischemia time; prevalence of obesity and 
diabetes; left ventricular hypertrophy; post-transplant 
tumours; post-transplant cardiovascular episodes; 
appearance of first-time diabetes following transplant; 
acute rejection episodes and post-transplant tumours. 
Furthermore, there are no differences in follow-up 
time after transplant.  
Table 2 shows the characteristics of smoker 
transplanted patients, as they were randomised to the 
intervention or control groups, in relation to exposure 
to tobacco at the baseline assessment phase. Tobacco 
exposure was assessed in accordance with the 
following factors: self-reported smoking; nicotine 
dependence; motivation to stop smoking and the 
smoking habit cessation stage. This table reveals that 
the groups are comparable in terms of self-reported 
smoking; nicotine dependence (Fagerström test); 
motivation to stop smoking (Richmond test) and the 
smoking cessation stage (Prochaska and DiClemente 
stages). 
Outcomes and estimation 
The assessment of the follow-up results is shown 
in Table 3, at 3, 6, 9, and 12 months following 
intervention. 
Significant differences were observed at 12 
months between the intervention and control groups 
in the carbon monoxide exhaled by co-oximetry 
(ppm) (6.1±6.8 vs. 9.7±10.2 ppm; p=0.028), as well as 
in the carboxyhaemoglobin exhaled by Co-oximetry 
(% COHb) (1.2±1.2 vs. 2.0±2.4%; p=0.039). The values 
of positive cotinine urine were also statistically 
different between the intervention group and the 
control group at the end of the study (p=0.018): in the 
case of the intervention group positive prevalence 
stood at 53.4%, compared with 74.2% in the control 
group. Statistically significant differences were also 
observed between the intervention and control 
groups at various stages of the follow-up in terms of 
the smoking habit cessation stage based on the 
Prochaska and DiClemente stages: at 12 months there 
were more patients at the smoking habit cessation 




stage in the intervention group than in the control 
group (46.6% vs 32.3%). The same trend was observed 
at 6 months. No significant differences were 
registered between the groups in terms of the 
following variables: the self-reported smoking 
(number of cigarettes per day); smoking rates (%), 
nicotine dependence (Fagerström test) and motivation 
to stop smoking (Richmond test). Although no 
differences were observed between the two groups in 
terms of the self-reported smoking (number of 
cigarettes per day), this value proved to be slightly 
higher among the control group than the intervention 
group throughout the follow-up period and the same 
trend was observed in the case of nicotine dependence 
(Fagerström test). 
 
Table 1. Characteristics of the patients according to the 
intervention or control group 







n (%) Mean 
(±SD) 
n (%) p 
Age at transplant (years) 42.8±11.0  43.5±12.4  0.742 
Transplanted time (years) 5.4±6.2  5.4±5.7  0.718 
Age at start of clinical trial 
(years) 
48.2±11.0  48.9±11.5  0.745 
Gender     0.967 










      
Pre-transplant comorbidity      
Duration of renal replacement 
therapy before transplantation 
(years)  
4.0±4.1  4.7±6.3  0.564 
Pre-transplant cholesterol 
(mg/dl) 
148.5±38.6  142.0±40.4  0.379 
Body mass index (IMC≥30)  9 (16.1)  3 (5.0) 0.068 
Pre-transplant diabetes   4 (6.8)  6 (9.5) 0.581 





Previous malignancies  1 (1.7)  2 (3.29) 0.519 
Cardiovascular events before 
transplantation 
 4 (6.8)  5 (7.9) 0.807 
      
Post-transplant comorbidity      
Cold ischemia time (hours) 18.3±8.4  20.1±7.7  0.268 
Obesity (BMI≥30)  11 
(19.3) 
 6 (10.0) 0.154 










Neoplasms after transplantation  5 (8.5)  3 (4.8) 0.322 
Cardiovascular events after 
transplantation 
 4 (6.8)  7 (11.1) 0.404 




 6 (9.5) 0.146 
Acute rejection episodes  6 (10.2)  11(17.5) 0.245 
      
Follow-up       
Follow-up time after 
transplantation (years) 
6.8±6.4  6.7±5.7  0.904 
 
As for the losses in each group, say that at 3 and 
6 months there was no loss, both in the control group 
and in the intervention. At 9 months there was a loss 
in the intervention group and at 12 months a loss in 
the control group. 
 
Table 2. Baseline assessment of tobacco exposure in relation to: 
self-reported smoking, nicotine dependence, motivation for giving 






 Mean (±SD) Mean (±SD) p 
Pattern of tobacco use (cigarettes/day)    
At what age did you start smoking? 18.0±4.8 17.5±5.3 0.593 
How many cigarettes did you smoke 
before the transplant? 
16.6±11.3 16.2±10.4 0.838 
How many cigarettes did you smoke at 
the time of the transplant? 
11.7±10.7 10.8±8.5 0.617 
What is the consumption of cigarettes at 
the beginning of the trial? 
12±9.1 12.5±8.3 0.772 
Nicotine dependence (Fagerström test) 1.54±1.8 1.94±2.3 0.545 
Motivation for giving up smoking 
(Richmond test) 
6.1±2.3 6.1±2.0 0.930 
    
 n (%) n (%)  
Positive urine cotinine test 59 (100) 63 (100) -- 
Fagerström test by categories   0.153 
≤ 4 Low dependence 56 (94.9) 53 (84.1)  
5-6 Moderate dependence 2 (3.4) 6 (9.5)  
≥ 7 High dependence 1 (1.7) 4 (6.3)  
Motivational stages of change 
(Prochaska and DiClemente’s stages) 
  0.950 
Pre-contemplation 33 (54.0) 34 (54.0)  
Contemplation 7 (11.9) 7 (11.1)  
Preparation 19 (22.2) 22 (34.9)  
Richmond test by categories   0.805 
≥7 High motivation 24 (44.4) 23 (42.6)  
5-6 Average Motivation 18 (33.3) 21 (38.9)  
≤4 Low motivation 12 (22.2) 10 (18.5)  
 
Concordance between self-reported smoking 
and the positive cotinine urine during follow-up, 
measured by the Kappa index, is shown in Table 4. 
This table shows a high degree of concordance 
between both measurements. A number of other 
variables were also assessed, including the sensitivity, 
specificity and predictive values of self-reported 
smoking in relation to the results obtained from the 
cotinine in urine test. The results revealed high 
sensitivity, specificity and predictive value levels. The 
low levels of negative likelihood ratios indicate that 
patient negation of exposure to smoking does not rule 
this out. In contrast, the positive likelihood ratio 
which registered such high values such as those 
recorded at 9 months (40.41) indicates that a positive 
answer practically confirms exposure.  
The relation between the response at 12 months 
to the cotinine urine test (positive vs. negative) and 
the various baseline variables together with the 
assignment group are shown in Table 5. The 
univariate analysis shows that the response at 12 
months is associated with baseline self-reported 
smoking (cigarettes per day), motivation to stop 
smoking (Richmond test) and the study group. In the 
case of the (OR adjusted) multivariate analysis, after 
considering the variables age at start of trial, 




self-reported smoking, nicotine dependence 
(Fagerström test), motivation to stop smoking 
(Richmond test), gender and assigned group, the 
following variables were noted as having an 
independent effect on predicting a positive cotinine 
urine test: self-reported smoking (cigarettes per day), 
baseline, motivation to stop smoking measured in 
accordance with the Richmond test and the group 
assigned to the study. Forming part of the 
intervention group implied a significant reduction in 
the risk of showing a positive cotinine urine test (OR 
0.39; 95% IC: 0.17-0.89). In turn, a greater motivation 
to stop smoking reduced the risk of testing positive 
(OR 0.83; 95% CI: 0.68-0.99) whilst self-reported 
smoking (cigarettes per day) increased this risk. The 
higher the number of cigarettes smoked, the greater 
the risk of a positive result (OR 1.09; 95%CI: 1.02-1.16). 
The relationship of baseline self-reported smoking 
and motivation to stop smoking with the probability 
of a positive urinary cotinine test at 12 months, in each 
of the groups of study, is shown in Figs 2 and 3. A 
higher self-reported smoking and a lower motivation 
to quit smoking are related to a higher probability of a 
positive test. On the other hand, patients in the 
intervention group showed a lower probability of a 
positive cotinine test. 
Cotinine urine test results were used to 
determine the clinical relevance of the intervention, 
calculating the associated RR (relative risk), RRR 
(Relative risk reduction), ARR (absolute risk 
reduction) and NNT (number needed to treat) at 
different time points in the follow-up (Table 6). At 12 
months, use of Co-oximetry reduce positive test 
results by 28% in relation to the brief advisory session 
alone, resulting in 12 patients needed to treat in order 
for one to quit smoking. 
 
Table 3. Outcome measures during the follow-up by group 
 3 months 6 months 9 months 12 months 
 IG CG  IG CG  IG CG  IG CG  
 Mean±SD Mean±SD p Mean±SD Mean±SD p Mean±SD Mean±SD p Mean±SD Mean±SD p 
Pattern of tobacco use (Cigarettes/day) 5.6±6.0 6.2±6.6 0.614 5.2±5.9 5.7±6.5 0.625 4.8±6.1 5.5±6.4 0.532 5.1±6.4 5.6±6.8 0.405 
Pattern of tobacco use (Smoking %) 39 (66.1) 47(74.6) 0.304 40 (67.8) 46 (73.0) 0.528 34 (58.6) 43 (68.3) 0.271 31 (53.4) 42 (67.7) 0.109 
CO levels in exhaled air by Co-oximetry (ppm) 6.8±6.8   6.7±7.8   5.8±6.7   6.1±6.8 9.7±10.2 0.028 
%COHb 1.5±2.0   1.5±2.5   1.1±1.2   1.2±1.2 2.0±2.4 0.039 
Nicotine dependence (Fagerström test) 0.9±1.2 1.5±2.0 0.338 0.7±1.6 1.3±1.9 0.141 0.9±1.6 1.3±2.0 0.837 1.1±1.6 1.3±2.0 0.976 
Motivation for giving up smoking (Richmond test) 5.9±1.8 6.1±1.6 0.598 6.3±1.7 6.4±1.8 0.892 6.6±1.6 6.7±1.6 0.869 6.6±1.7 6.1±2.1 0.595 
 n (%) n (%) p n(%) n(%) p n(%) n(%) p n(%) n(%) p 
Positive cotinine urine test 42 (71.2) 50 (79.4) 0.294 41(69.5) 48 (76.2) 0.405 35 (60.3) 44 (69.8) 0.273 31(53.4) 46 (74.2) 0.018 
Fagerström test              
≤ 4 Low dependence 39 (100) 43 (91.5)  38 (95.0) 43 (93.5)  34 (97.1) 39 (90.7)  30 (96.8) 38 (90.5)  
5-6 Moderate dependence 0 2 (4.3)  1 (2.5) 1 (2.2)  0 2 (4.7)  0 2 (4.8)  
≥ 7 High dependence 0 2 (4.3)  1 (2.5) 2 (4.3)  1 (2.9) 2 (4.7)  1 (3.2) 2 (4.8)  
Motivational stages of change (Prochaska and 
DiClemente’s stages) 
  0.518   0.010   0.331   0.027 
Pre-contemplation 9 (15.3) 11 (17.5)  10 (16.9) 8 (12.7)  13 (22.4) 10 (15.9)  14 (24.1) 9 (14.5)  
Contemplation 16 (27.1) 24 (38.1)  8 (13.6) 25 (39.7)  6 (10.3) 13 (20.6)  4 (6.9) 15 (24.2)  
Preparation 14 (23.7) 12 (19.0)  22 (37.3) 13 (20.6)  16 (27.6) 20 (31.7)  13 (22.4) 18 (29.0)  
Cessation 20 (33.9) 16 (25.4)  19 (32.2) 17 (27.0)  23 (39.7) 20 (31.7)  27 (46.6) 20 (32.3)  
Richmond test    0.214   0.694   0.716   0.378 
≥7 High motivation 13 (40.6) 19 (46.3)  15 (50.0) 18 (54.5)  8 (47.1) 15 (57.7)  3 (37.5) 5 (55.6)  
5-6 Moderate motivation 11 (34.4) 18 (43.9)  9 (30.0) 11 (33.3)  8 (47.1) 9 (34.6)  5 (62.5) 3 (33.3)  
≤4 Low motivation 8 (25.0) 4 (9.8)  6 (20.0) 4 (12.1)  1 (5.9) 2 (7.7)  0 1 (11.1)  
 

























































Positive likelihood ratio -- -- 40.41 
5.82-280.33 
-- 








Kappa index 0.876 0.939 0.928 0.929 
PPV: positive predictive value; NPV: negative predictive value 




Table 5. Characteristics of the patients according to urine cotinine test at 12 months according to different variables. Univariate and 
multivariate regression analysis 
 Positive urine cotinine test 
at 12 months 
Negative urine cotinine test 
at 12 months 
   
 Mean±SD Mean±SD p  crude OR* (95%CI) adjusted OR** 
(95%CI) 
Transplant age (years) 42.9±11.2 42.9±12.4 0.996 1.0 (0.97-1.03)  
Transplanted time (years) 5.0±5.2 6.1±7.0 0.298 0.97 (0.90-1.03)  
Age at the start of the clinical trial (years) 47.9±10.7 49.0±11.9 0.581 0.99 (0.96-1.02) 0.99 (0.96-1.02) 
Pattern of tobacco use (Cigarettes/day) 14.0±8.9 9.0±7.4 0.004 1.09 (1.03-1.15) 1.09 (1.02-1.16) 
Nicotine dependence (Fagerström test) 3.4±1.1 3.1±1.0 0.099 1.37 (0.94-2.00) 1.03 (0.65-1.62) 
Motivation for giving up smoking 
(Richmond test) 
5.9±2.1 6.9±2.5 0.026 0.81 (0.68-0.98) 0.83 (0.68-0.99) 
      
 n (%) n (%)    
Gender   0.915   
 Female 24(64.9%) 13(35.1%)  1  
 Male 53(63.8%) 30(36.2%)  0.92 (0.43-2.12) 0.60 (0.23-1.55) 
Group   0.019   
 Control Group 46(74.2%) 16(25.8%)  1  
 Intervention Group 31(53.4%) 27(46.6%)  0.40 (0.18-0.86) 0.39 (0.17-0.89) 
*Crude OR: OR from univariate analysis 
** Adjusted OR: OR after logistic regression analysis 
 
 
Figure 2. Probability of positive cotinine urine test (12 month) in relation with consumption of cigarettes/day at the beginning of the trial according to group 
 
Table 6. Clinical relevance of the results 
 Positive cotinine urine test  
 3 months 6 months 9 months 12 months 12 months 
95% CI 
Smoking rates      
 Intervention Group 71.2% 69.5% 60.3% 53.4%  
 Control Group 79.4% 76.2% 69.8% 74.2%  
p value 0.294 0.405 0.273 0.018  
Clinical relevance      
 RR 0.90 0.91 0.85 0.72 0.54-0.96 
 RRR 0.10 0.09 0.15 0.28 0.04-0.46 
 ARR 0.08 0.07 0.11 0.20 0.04-0.37 
 NNT 12.23 14.93 9.51 4.88 2.68-27.28 
RR: relative risk 
RRR: relative risk reduction 
ARR: absolute risk reduction 
NNT: number needed to treat 
 
Discussion 
A previous study conducted by our group 
revealed that patients who continue to smoke 
following kidney transplant have increased risk of 
cardiovascular events in comparison with 
non-smokers. Furthermore, the rate of such episodes 
also increases in line with exposure time [14]. The 
study revealed clinical relevance regarding the 
cardiovascular episode rates and giving up smoking. 






Figure 3. Probability of positive cotinine urine test (12 month) in relation with Richmond test at the beginning of the trial according to group 
 
Of all the possible interventions, motivation to 
lead a healthy lifestyle and giving up smoking are the 
simplest and least expensive options that can be 
applied by means of a brief advisory session and 
Co-oximetry. Other possible more expensive 
interventions [31-34] could be drugs, economic 
incentives, acupuncture, electronic cigarretes, the cost 
of a coximeter is approximately € 60 and we can use it 
in all our patients only by changing the mouthpiece. 
In this clinical trial, following Co-oximetry, 
significant reductions were observed in the following 
variables: carbon monoxide exhaled by Co-oximetry, 
cotinine urine test and changes in the intervention 
group and control group in the Prochaska and 
DiClemente transtheoretical model of change. There is 
a high degree of concordance between the 
self-reported smoking and the cotinine urine test. 
These reductions are consistent with other 
publications referred to above that prove the 
effectiveness of this type of intervention [21,22,24,25].  
It seems worthy to mention how both 
interventions, brief advice in smoking cessation and 
brief advice in smoking cessation + CO-oximetry, 
remarkably improved some outcomes, such as about a 
50% lower number of self-reported cigarettes smoked 
per day in both groups at the end of the study. 
After considering age at the start of the trial, 
reported smoking, the Fagerström nicotine 
dependence test, motivation to stop smoking in 
accordance with the Richmond test, patient sex and 
the trial group assigned, we observed that the 
following variables have an independent effect on the 
prediction of a positive cotinine urine test 12 months: 
belonging to the study control group, motivation to 
stop smoking in accordance with the Richmond 
baseline test and baseline reported smoking. 
Belonging to the intervention group implies a 
significant reduction in the risk of positive cotinine 
urine testing. A greater motivation to stop smoking 
(by means of the Richmond test) reduces this risk 
whilst higher self-reported exposure to smoking will 
increase it. 
To the best of our knowledge, this study is the 
first to prove the effectiveness of co-oximetry in 
reducing smoking behavior in this patient subgroup. 
We have been unable to find articles on anti-smoking 
intervention among patients with kidney failure or 
kidney transplanted patients[23]. We found articles 
that recommend regular follow-up of transplant 
smokers so that they quit smoking [35] In this sense, 
this research contributes new evidence for the kidney 
transplanted patient subgroup. 
Although it is not the outcome of the trial, it 
seems worthy to mention how both interventions 
remarkably improved some outcomes, such as about a 
50% lower number of self-reported cigarettes smoked 
per day in both groups. 
The limitations of this study are discussed 
below:  
a) Selection bias: This study can only be applied 
to this patient subgroup (kidney transplant recipients 
that smoke) in reducing exposure to smoking. The 
results may be due to selection bias as it is applicable 
to a subgroup of transplanted patients that smoke, 




although this is doubtful as the results are consistent 
with those obtained with other patient subgroups and 
at all events, the comparability of the groups at the 
start of the trial has been proved.  
b) In order to minimise information bias, the 
questionnaires employed were drawn up by skilled 
professionals.  
Questions often arise regarding the validity of 
the self-reported smoking variable as smokers are 
generally believed to underestimate the number of 
cigarettes they actually smoke [36]. For the purpose of 
our study, we considered the validity and 
concordance of the self-reported results with the 
biochemical findings. The results indicated a high 
degree of concordance and validity in this patient 
subgroup.  
In order to avoid classification errors and the 
tendency towards self-deception shown by smokers, 
due to the information bias we recommend 
biochemical measures in order to validate 
self-reported smoking patterns among patients taking 
part in the assessment studies[37]. This study uses 
both the self-reporting smoking variable and 
biochemical means.  
c) For the purpose of minimising any possible 
confusion regarding other variables, our comparative 
study addressed not only co-morbidity, but also prior 
exposure to smoking. Furthermore, and in order to 
consider the various confusion variables, a logistic 
regression analysis was carried out that took into 
account not only the group assigned but also 
self-reported smoking, nicotine dependence, 
motivation to stop smoking, age, gender and the 
transplant time.  
Conclusions 
At 12 months the study showed a fall in carbon 
monoxide and carboxyhaemoglobin levels in the air 
exhaled by co-oximetry in the intervention group in 
comparison with the control group. Likewise, the 
positive cotinine urine test showed significantly lower 
results in the intervention group than in the control 
group.  
Also at 12 months, the Prochaska and Di 
Clemente transtheoretical model of change revealed a 
significant difference between the intervention group 
and the control group, consisting of a greater 
prevalence of the smoking cessation stage among the 
former group in comparison with the latter. The same 
trend was also observed at 6 months.  
No significant differences were observed 
between the two groups in terms of the self-reported 
smoking (number of cigarettes per day), smoking 
rates (%), nicotine dependence (Fagerström test) and 
motivation to stop smoking (Richmond test). 
Although no differences were observed in 
self-reported smoking (number of cigarettes per day) 
between the two groups, the number was slightly 
higher in the control group than in the intervention 
group throughout the entire follow-up period. A 
similar trend was noted in the nicotine dependence 
test (Fagerström test). There is a high degree of 
concordance between the self-reported smoking and 
the cotinine urine test.  
After considering age at the start of the trial, 
reported smoking, the Fagerström nicotine 
dependence test, motivation to stop smoking in 
accordance with the Richmond test, patient sex and 
the trial group assigned, we observed that the 
following various have an independent effect on the 
prediction of a positive cotinine urine test 12 months: 
belonging to the study control group, motivation to 
stop smoking in accordance with the Richmond 
baseline test and baseline reported smoking. 
Belonging to the intervention group implies a 
significant reduction in the risk of positive cotinine 
urine testing. A greater motivation to stop smoking 
(by means of the Richmond test) reduces this risk 
whilst higher self-reported exposure to smoking will 
increase it.  
In short, the use of Co-oximetry in kidney 
transplanted patients that smoke is a clinically 
relevant intervention for the reduction of exposure to 
smoking, as indicated by the relative risk reduction, 
absolute risk reduction and the number of patients 
needed to treat in order to get one patient to stop 
smoking.  
The effectiveness of Co-oximetry in reducing 
exposure to smoking is confirmed in this patient 
subgroup. The intervention is easy to apply, 
inexpensive and of major importance in the 
prevention of cardiovascular risk.  
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